Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
221 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2016', provides an overview of the Pancreatic Ductal Adenocarcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pancreatic Ductal Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pancreatic Ductal Adenocarcinoma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Pancreatic Ductal Adenocarcinoma - The report reviews pipeline therapeutics for Pancreatic Ductal Adenocarcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Pancreatic Ductal Adenocarcinoma therapeutics and enlists all their major and minor projects - The report assesses Pancreatic Ductal Adenocarcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Pancreatic Ductal Adenocarcinoma Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Pancreatic Ductal Adenocarcinoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Pancreatic Ductal Adenocarcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Pancreatic Ductal Adenocarcinoma Overview 10 Therapeutics Development 11 Pipeline Products for Pancreatic Ductal Adenocarcinoma - Overview 11 Pipeline Products for Pancreatic Ductal Adenocarcinoma - Comparative Analysis 12 Pancreatic Ductal Adenocarcinoma - Therapeutics under Development by Companies 13 Pancreatic Ductal Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes 15 Pancreatic Ductal Adenocarcinoma - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Pancreatic Ductal Adenocarcinoma - Products under Development by Companies 19 Pancreatic Ductal Adenocarcinoma - Products under Investigation by Universities/Institutes 21 Pancreatic Ductal Adenocarcinoma - Companies Involved in Therapeutics Development 22 AbbVie Inc. 22 BerGenBio AS 23 Celgene Corporation 24 Clovis Oncology, Inc. 25 Coare Biotechnology, Inc. 26 Concordia Healthcare Corp. 27 FibroGen, Inc. 28 Forty Seven Inc. 29 Gilead Sciences, Inc. 30 Halozyme Therapeutics, Inc. 31 Immodulon Therapeutics Ltd. 32 Immunomedics, Inc. 33 Incuron, LLC 34 Incyte Corporation 35 Inovio Pharmaceuticals, Inc. 36 MedImmune, LLC 37 Medisyn Technologies, Inc. 38 Merck & Co., Inc. 39 Nerviano Medical Sciences S.r.l. 40 OncoMed Pharmaceuticals, Inc. 41 Oryx GmbH & Co. KG 42 Sillajen Biotherapeutics 43 Tara Immuno-Oncology Therapeutics LLC 44 Tokai Pharmaceuticals, Inc. 45 Pancreatic Ductal Adenocarcinoma - Therapeutics Assessment 46 Assessment by Monotherapy Products 46 Assessment by Combination Products 47 Assessment by Target 48 Assessment by Mechanism of Action 51 Assessment by Route of Administration 53 Assessment by Molecule Type 55 Drug Profiles 57 BGB-324 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 CBL-0137 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 CBT-1111 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 CBT-3112 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 demcizumab - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 durvalumab - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 durvalumab + tremelimumab - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 epacadostat - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 FG-3019 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 galeterone - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Hu-5F9G4 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 ibrutinib - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 idelalisib - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 IMM-101 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 INCB-50465 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 INO-1400 - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 ipafricept - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 itacitinib adipate - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 JX-929 - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 MK-0752 - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 MK-8628 - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 momelotinib dihydrochloride - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 MRK-003 - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 MT-477 - Drug Profile 109 Product Description 109 Mechanism of Action 109 R&D Progress 109 NMSP-715 - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 Oligonucleotide to Inhibit IDO1 for Pancreatic Ductal Adenocarcinoma - Drug Profile 111 Product Description 111 Mechanism of Action 111 R&D Progress 111 paclitaxel albumin bound - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 Parvoryx - Drug Profile 116 Product Description 116 Mechanism of Action 116 R&D Progress 116 PEGPH-20 - Drug Profile 117 Product Description 117 Mechanism of Action 117 R&D Progress 117 porfimer sodium - Drug Profile 120 Product Description 120 Mechanism of Action 120 R&D Progress 120 PSL-001 - Drug Profile 122 Product Description 122 Mechanism of Action 122 R&D Progress 122 rucaparib phosphate - Drug Profile 123 Product Description 123 Mechanism of Action 123 R&D Progress 123 sacituzumab - Drug Profile 126 Product Description 126 Mechanism of Action 126 R&D Progress 126 SBP-101 - Drug Profile 128 Product Description 128 Mechanism of Action 128 R&D Progress 128 siG12D-LODER - Drug Profile 130 Product Description 130 Mechanism of Action 130 R&D Progress 130 Small Molecule to Inhibit Wnt Signal and eIF5A for Pancreatic Cancer - Drug Profile 132 Product Description 132 Mechanism of Action 132 R&D Progress 132 Small Molecules to Modulate GLT-1 for Pancreatic Ductal Adenocarcinoma - Drug Profile 133 Product Description 133 Mechanism of Action 133 R&D Progress 133 vantictumab - Drug Profile 134 Product Description 134 Mechanism of Action 134 R&D Progress 134 Pancreatic Ductal Adenocarcinoma - Recent Pipeline Updates 136 Pancreatic Ductal Adenocarcinoma - Dormant Projects 214 Pancreatic Ductal Adenocarcinoma - Discontinued Products 215 Pancreatic Ductal Adenocarcinoma - Product Development Milestones 216 Featured News & Press Releases 216 Jan 27, 2016: FibroGen Announces Early Phase 2 Data From a Clinical Study of FG-3019 in Combination With Chemotherapy as Neoadjuvant in Locally Advanced, Unresectable Pancreatic Cancer 216 Nov 09, 2015: Compelling Preclinical Data on Sun BioPharma's SBP-101 Presented at the 2015 American Pancreatic Association (APA) Annual Meeting 217 Oct 20, 2015: Sun BioPharma to Present Three Abstracts at the 2015 American Pancreatic Association Annual Meeting 218 Jun 25, 2013: Cleveland BioLabs And Incuron Announce Poster Presentation At ESMO 15th World Congress On Gastrointestinal Cancer 218 Appendix 220 Methodology 220 Coverage 220 Secondary Research 220 Primary Research 220 Expert Panel Validation 220 Contact Us 220 Disclaimer 221
List of Tables
Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H1 2016 11 Number of Products under Development for Pancreatic Ductal Adenocarcinoma - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Number of Products under Development by Companies, H1 2016 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2016 21 Pancreatic Ductal Adenocarcinoma - Pipeline by AbbVie Inc., H1 2016 22 Pancreatic Ductal Adenocarcinoma - Pipeline by BerGenBio AS, H1 2016 23 Pancreatic Ductal Adenocarcinoma - Pipeline by Celgene Corporation, H1 2016 24 Pancreatic Ductal Adenocarcinoma - Pipeline by Clovis Oncology, Inc., H1 2016 25 Pancreatic Ductal Adenocarcinoma - Pipeline by Coare Biotechnology, Inc., H1 2016 26 Pancreatic Ductal Adenocarcinoma - Pipeline by Concordia Healthcare Corp., H1 2016 27 Pancreatic Ductal Adenocarcinoma - Pipeline by FibroGen, Inc., H1 2016 28 Pancreatic Ductal Adenocarcinoma - Pipeline by Forty Seven Inc., H1 2016 29 Pancreatic Ductal Adenocarcinoma - Pipeline by Gilead Sciences, Inc., H1 2016 30 Pancreatic Ductal Adenocarcinoma - Pipeline by Halozyme Therapeutics, Inc., H1 2016 31 Pancreatic Ductal Adenocarcinoma - Pipeline by Immodulon Therapeutics Ltd., H1 2016 32 Pancreatic Ductal Adenocarcinoma - Pipeline by Immunomedics, Inc., H1 2016 33 Pancreatic Ductal Adenocarcinoma - Pipeline by Incuron, LLC, H1 2016 34 Pancreatic Ductal Adenocarcinoma - Pipeline by Incyte Corporation, H1 2016 35 Pancreatic Ductal Adenocarcinoma - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 36 Pancreatic Ductal Adenocarcinoma - Pipeline by MedImmune, LLC, H1 2016 37 Pancreatic Ductal Adenocarcinoma - Pipeline by Medisyn Technologies, Inc., H1 2016 38 Pancreatic Ductal Adenocarcinoma - Pipeline by Merck & Co., Inc., H1 2016 39 Pancreatic Ductal Adenocarcinoma - Pipeline by Nerviano Medical Sciences S.r.l., H1 2016 40 Pancreatic Ductal Adenocarcinoma - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016 41 Pancreatic Ductal Adenocarcinoma - Pipeline by Oryx GmbH & Co. KG, H1 2016 42 Pancreatic Ductal Adenocarcinoma - Pipeline by Sillajen Biotherapeutics, H1 2016 43 Pancreatic Ductal Adenocarcinoma - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016 44 Pancreatic Ductal Adenocarcinoma - Pipeline by Tokai Pharmaceuticals, Inc., H1 2016 45 Assessment by Monotherapy Products, H1 2016 46 Assessment by Combination Products, H1 2016 47 Number of Products by Stage and Target, H1 2016 49 Number of Products by Stage and Mechanism of Action, H1 2016 52 Number of Products by Stage and Route of Administration, H1 2016 54 Number of Products by Stage and Molecule Type, H1 2016 56 Pancreatic Ductal Adenocarcinoma Therapeutics - Recent Pipeline Updates, H1 2016 136 Pancreatic Ductal Adenocarcinoma - Dormant Projects, H1 2016 214 Pancreatic Ductal Adenocarcinoma - Discontinued Products, H1 2016 215
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
